MedPath

Tavaborole

These highlights do not include all the information needed to use safely and effectively. See full prescribing information for . Initial U.S. Approval: 2014

Approved
Approval ID

dc68c727-a77a-432e-8308-e88aea241b58

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Nov 15, 2021

Manufacturers
FDA

Padagis US LLC

DUNS: 967694121

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Tavaborole

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0574-0157
Application NumberANDA211848
Product Classification
M
Marketing Category
C73584
G
Generic Name
Tavaborole
Product Specifications
Route of AdministrationTOPICAL
Effective DateJanuary 11, 2021
FDA Product Classification

INGREDIENTS (4)

PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT
EDETATE CALCIUM DISODIUMInactive
Code: 25IH6R4SGF
Classification: IACT
TAVABOROLEActive
Quantity: 43.5 mg in 1 mL
Code: K124A4EUQ3
Classification: ACTIB
ALCOHOLInactive
Code: 3K9958V90M
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Tavaborole - FDA Drug Approval Details